Hormonal contraception in women at risk of vascular and metabolic disorders: guidelines of the French Society of Endocrinology
- PMID: 23078975
- DOI: 10.1016/j.ando.2012.09.001
Hormonal contraception in women at risk of vascular and metabolic disorders: guidelines of the French Society of Endocrinology
Abstract
Hormonal contraceptive methods are widely used in France, including not only oral estrogen-progestin combinations but also non-oral estrogen-progestin delivery methods (patches, vaginal rings), as well as oral forms, implants and intra-uterine devices that deliver only a progestin. Hormonal contraception has only a modest impact on lipid and carbohydrate metabolism, but estrogen-progestin contraceptives have been linked to a variety of vascular risks. Overall, the risk of venous thrombosis is multiplied by a factor of about 4, depending on age, the compounds used, and other risk factors (including biological thrombophilia and a personal history of thrombosis), whereas the risk of arterial events is only increased in women with risk factors. Available data suggest there is no excess risk with progestin-based contraceptives, but far fewer studies have been conducted. At the initiative of the French Society of Endocrinology, an expert group met in 2010 in order to reach a consensus on the use of hormonal contraceptive methods in women with vascular or metabolic risk factors, based on available data and international guidelines published by WHO in 2009 and subsequently adapted to the United States context. The following text, intentionally limited to hormonal contraception, is intended to serve as a guide when prescribing in specific clinical situations, such as a family or personal history of arterial or venous thromboembolism, or the existence of cardiovascular risk factors (hypertension, smoking, diabetes, dyslipidemia, obesity).
Copyright © 2012. Published by Elsevier Masson SAS.
Similar articles
-
[Hormonal contraception and vascular risk: CNGOF Contraception Guidelines].Gynecol Obstet Fertil Senol. 2018 Dec;46(12):823-833. doi: 10.1016/j.gofs.2018.10.007. Epub 2018 Oct 30. Gynecol Obstet Fertil Senol. 2018. PMID: 30389542 French.
-
Risks and mechanisms of cardiovascular events in users of oral contraceptives.Am J Obstet Gynecol. 1988 Jun;158(6 Pt 2):1646-52. doi: 10.1016/0002-9378(88)90203-7. Am J Obstet Gynecol. 1988. PMID: 3287935 Review.
-
[Combined contraceptives and cardiovascular risk].Contracept Fertil Sex (Paris). 1987 Dec;15(12 Suppl):1-8. Contracept Fertil Sex (Paris). 1987. PMID: 12315199 French.
-
Hormonal contraception.N Engl J Med. 1993 May 27;328(21):1543-9. doi: 10.1056/NEJM199305273282108. N Engl J Med. 1993. PMID: 8479492 Review.
-
[Cardiovascular risks of combined oral contraceptives - beyond the French controversy].Gynecol Obstet Fertil. 2014 Mar;42(3):174-81. doi: 10.1016/j.gyobfe.2014.01.024. Epub 2014 Feb 26. Gynecol Obstet Fertil. 2014. PMID: 24582295 French.
Cited by
-
Dunnigan lipodystrophy syndrome: French National Diagnosis and Care Protocol (PNDS; Protocole National de Diagnostic et de Soins).Orphanet J Rare Dis. 2022 Apr 19;17(Suppl 1):170. doi: 10.1186/s13023-022-02308-7. Orphanet J Rare Dis. 2022. PMID: 35440056 Free PMC article.
-
Oral contraceptives in adolescents: a retrospective population-based study on blood pressure and metabolic dysregulation.Eur J Clin Pharmacol. 2024 Jul;80(7):1097-1103. doi: 10.1007/s00228-024-03671-z. Epub 2024 Mar 30. Eur J Clin Pharmacol. 2024. PMID: 38554180
-
Effects of hormonal contraceptives on lipid profile among women attending family planning unit in Goba Town Public Health Facilities, Bale, Southeast Ethiopia: a comparative cross-sectional study.Reprod Health. 2023 Dec 19;20(1):185. doi: 10.1186/s12978-023-01727-4. Reprod Health. 2023. PMID: 38115027 Free PMC article.
-
Contraception for women with diabetes: challenges and solutions.Open Access J Contracept. 2016 Mar 3;7:11-18. doi: 10.2147/OAJC.S56348. eCollection 2016. Open Access J Contracept. 2016. PMID: 29386933 Free PMC article. Review.
-
Thromboembolic events in women exposed to hormonal contraception or cyproterone acetate in 2012: a cross-sectional observational study in 30 French public hospitals.Drug Saf. 2014 Apr;37(4):269-82. doi: 10.1007/s40264-014-0149-8. Drug Saf. 2014. PMID: 24634164
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous